German-Chinese cooperation

ISAS Participates in Drug Development for Heart Patients

Dortmund, 5th February 2020

The development of a new drug for the treatment of heart failure and cardiac hypertrophy is a primary goal of “ChInValue – NRW–China Cooperations: GRK5 Inhibitors”. The project is being coordinated by the Lead Discovery Center (LDC) and conducted in cooperation with the Leibniz Institute for Analytical Sciences (ISAS) and two Chinese partners: Shanghai Jemincare Pharmaceutical Co. and Makohs Biotech. The German–Chinese consortium will devote itself to the fight against cardiac insufficiency and hypertrophy until the end of 2022. The German partners are being funded by a grant of around EUR 1 million from the German Federal Ministry of Education and Research (BMBF).

Die Arbeiten des Konsortiums werden sich auf die Proteinkinase GRK5 fokussieren, welche bisher in der Arzneimittelentwicklung wenig beachtet wurde. — Research will focus on GRK5, a protein kinase that has so far received little attention in drug development, despite being implicated in the development of heart failure or hypertrophic heart muscle in the vast majority of cases.

Research will focus on GRK5, a protein kinase that has so far received little attention in drug development, despite being implicated in the development of heart failure or hypertrophic heart muscle in the vast majority of cases. The aim of the project is to develop low-molecular-weight substances that inhibit the pathological processes mediated by GRK5.

“Our ambitious goal is to develop a drug candidate that is ready to enter preclinical development by the end of this three-year project,” says LDC’s Managing Director and CSO, Dr Bert Klebl.

“We hope to develop an effective new therapy from which heart disease patients can profit in the near future,” explains the ISAS scientific director and head of the Biomedical Research Department, Prof. Kristina Lorenz, a pharmacologist specializing in the treatment of cardiovascular diseases.

Financial support is being provided by the German Federal Ministry of Education and Research as part of its funding programme “InterSPIN – internationalization of leading-edge clusters, forward-looking projects and comparable networks”. Within this context, BIO.NRW and BIO Clustermanagement NRW GmbH have conceived and realized the internationalization alliance „NRW-China Cooperations: A strategic perspective for innovative life science SME value chains”, of which this project in the fight against heart failure is a part.

Further press releases

28th September 2026

Ceramides Drive Metastasis in Colorectal Cancer

Why do individual colorectal cancer cells form metastases? An international research team, including researchers from ISAS, has identified a mechanism whereby the body’s own synthesis of ceramides can promote the metastasis of colorectal cancer. The study also revealed the role played by the fat content of the diet. The researchers have now published the results of the preclinical model in Science.

13th July 2026

Fabry Disease: a Molecular Map of Lipids in Tissue

A new technique developed at ISAS combines Raman microscopy and mass spectrometry imaging, and it demonstrates that, for the first time, the spatial distribution of lipids can be visualised at cellular and subcellular levels – including further essential information. The new analytical method holds high potential for the diagnosis and treatment of conditions such as Fabry disease, in which molecules undergo local changes within the tissue.

2nd July 2026

Biomedical Image Analysis with AI

Dr Jianxu Chen is taking up a professorship in AI for Biomedical Analysis at the University of Duisburg-Essen. With his research group at ISAS, he is developing AI methods that can be used to comprehensively analyse enormous quantities of complex microscopy images.

29th June 2026

It's What's Inside That Counts: Neutrophils Form Distinct Subtypes

Neutrophils can be divided into two distinct subgroups with completely different functions. The surface protein CD177 plays a decisive role in this. For the first time, researchers from the Faculty of Medicine at the University of Duisburg-Essen and ISAS have been able to demonstrate, using a new integrated proteomics and lipidomics analysis, that the molecular signatures in CD177-defined neutrophils differ significantly from one another. The presence of this surface protein has implications for disease progression, for example in head and neck tumours.

26th November 2025

New Drug Candidates for the Treatment of Heart Failure

Researchers from North Rhine-Westphalia are working on a new therapeutic approach for the treatment of heart failure as part of the recently launched HI-FIVE project. They are developing active substances that specifically inhibit an important enzyme with the aim of closing gaps in the care of patients with heart failure.

26th September 2025

Microbiome Research: EU Network METAMIC 3 Is Looking for Doctoral Candidates

In the new EU network METAMIC 3, young scientists will be researching the role of microbiomes in the context of ‘One Health’ for their dissertations. Metaproteomics methods will be applied in this research. Furthermore, stays at various European institutions are part of the doctoral programme. The doctoral positions are now open for applications.

Prof. Dr. Robert Heyer is Head of the research group Multidimensional Omics Data Analysis at ISAS and coordinator of the network.